+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Novo Nordisk

  • ID: 4462205
  • Company Profile
  • July 2020
  • 67 pages
  • Pharma Intelligence
  • Novo Nordisk A/S
The publisher explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
  • Overview: Novo Nordisk continues to dominate the diabetes segment, but pricing pressure in the US will dampen overall sales growth during the forecast period.
  • Key Themes – [1] Novo Nordisk will maintain its dominance in diabetes with the launch of Rybelsus [2] Growth in Rest of World regions, especially China, is key to Novo Nordisk’s long-term revenue outlook [3] US volume growth and market share will remain strong, but pricing pressures, discounts, and rebates will limit revenue growth [4] Insulin biosimilars are a key risk to Novo Nordisk’s insulin franchises, but limited impact seen to date.
Model updates (2 June 2020)
  • Esperoct forecast adjusted lower.
Model updates (6 March 2020)
  • Tresiba forecast adjusted lower in the US due to continued pricing pressure
  • Xultophy forecast adjusted lower in the US due to continued pricing pressure
  • Levemir forecast adjusted lower in the US due to continued pricing pressure
  • NovoMix forecast adjusted lower in the US due to continued pricing pressure
  • NovoRapid forecast adjusted lower in the US due to continued pricing pressure
  • Victoza forecast adjusted lower in the US due to patient shifts to Ozempic
  • Ozempic forecast adjusted higher globally due to continued market share gains and GLP-1 class growth
  • Rybelsus forecast adjusted lower due to slower launch trend
  • Saxenda forecast adjusted lower due to future generic competition.
Model updates (8 November 2019)
  • Tresiba forecast adjusted lower in the US due to continued pricing pressure
  • Xultophy forecast adjusted lower in the US due to continued pricing pressure
  • Levemir forecast adjusted lower in the US due to continued pricing pressure
  • NovoMix forecast adjusted lower in the US due to continued pricing pressure
  • NovoRapid forecast adjusted lower in the US due to continued pricing pressure
  • Victoza forecast adjusted lower in the US due to patient shifts to Ozempic
  • Ozempic forecast adjusted higher globally due to continued market share gains and GLP-1 class growth
  • Saxenda forecast adjusted higher in the US and Rest of World due to strong demand.
Model updates (13 August 2019)
  • Ozempic forecast adjusted higher due to pace of product launch in the US and continued share gains for GLP-1 class globally; launch in Japan delayed until 2020
  • Victoza forecast adjusted lower due to pace of Ozempic cannibalization
  • NovoRapid forecast adjusted higher due to less patient shifting to FIAsp
  • FIAsp forecast adjusted lower due to less patient shifting from NovoRapid
  • NovoMix forecast adjusted higher due to less patient shifting to Ryzodeg
  • Ryzodeg forecast adjusted lower due to less patient shifting from NovoMix
  • Norditropin forecast adjusted higher due to realignment of patent expiration with NordiFlex and FlexPro devices
  • NovoSeven forecast adjusted higher due to lower impact from Hemlibra launch
  • Somapacitan launches delayed to 2020 and 2021.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Notable Quotes & Important Topics
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll